October 15, 2019
Cadwalader advised HealthCare Royalty Partners in connection with a revenue interest financing transaction with Karyopharm Therapeutics for up to $150 million to support the ongoing development and commercialization of XPOVIOTM (selinexor), Karyopharm’s oral SINE compound that is currently marketed in the United States for the treatment of patients with heavily pretreated multiple myeloma.
The Cadwalader team was led by partner Ira Schacter and included Joo Kim, Steve Lenkowsky and Solomon Brown.
our latest insights on the impact of COVID-19 to help you navigate this unprecedented environment.
Learn more about the event and watch the on-demand replay here.
Selections to the Lawdragon 500 are limited to no more than 500 lawyers in the country.
Our latest podcast covers the legacy of the “Car Wash” investigation and how Brazil fits into the global landscape of white-collar crime enforcement.